Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease - Slideshow
Argenx
Argenx Anonymous (not verified) Thu, 11/05/2026 - 18:31 field_thread_url https://cafepharma.com/boards/threads/argenx.665212/ board name...
Argenx
Argenx Anonymous (not verified) Mon, 10/19/2026 - 10:14 field_thread_url https://cafepharma.com/boards/threads/argenx.665212/ board name...
Lumexa Imaging Holdings, Inc. (LMRI) Q3 2026 Earnings Call Transcript
Annexon, Inc. (ANNX) Discusses Vonaprument Phase III ARCHER II Trial in Geographic Atrophy - Slideshow
<![CDATA[Innogen Licenses GLP-1 Therapy Efsubaglutide Alfa to Arcera]]>
Green Leaf Innovations (OTC: GRLF) Meets OTCID Disclosure Requirements Following Profitable Q2 2026 Results
Milestone follows Q2 2026 quarterly report filing and includes current financial disclosure, management certification, a verified company profile and transfer agent share reporting...
ER-100 – aging reversal drug first test results in the EYE with Glaucoma announced
Safety phase. 2 of 3 patients given LOW DOSES reported vision improvement. Phase 2 – Doses will now triple in size for next round. Today, at the American Academy of Ophthalmology A...
Turn fresh research into a full content calendar
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.